– Presentation highlights sure prime-line recordsdata from 12-week Portion 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –
BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ — Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a number one clinical-stage biopharmaceutical firm taking into consideration about cardiovascular illnesses, on the present time supplied that the CIRRUS-HCM summary became once chosen for a leisurely-breaking science presentation on the European Society of Cardiology (ESC) Congress, taking home August 28-31 in Munich, Germany. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to unhurried early contraction and pink meat up cardiac relaxation in symptomatic HCM whereas conserving systolic characteristic.
Leisurely-Breaking Science Presentation:
Title: CIRRUS-HCM: 12-Week Evaluate of the Safety and Efficacy of the Unique Cardiac Sarcomere Modulator EDG-7500 in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy
Presenter: Anjali Tiku Owens, M.D., Affiliate Professor of Medication within the Division of Cardiology on the Perelman College of Medication of the College of Pennsylvania
Date: Monday, August 31, 2026, 11:30 – 11:45 am CEST
Session: Reworking the coronary heart: unique therapies for myocardial illness and coronary heart failure
Space: Achgabat (Hall A3)
The presentation will almost certainly be accessible on the Edgewise web keep after it is supplied.
About CIRRUS-HCM
CIRRUS-HCM is a multi-share, open be conscious trial of EDG-7500 in participants with obstructive and nonobstructive HCM at over 20 clinical websites within the U.S. Segment A of the trial evaluated the security and tolerability of a single oral dose of EDG-7500 in participants with obstructive HCM (oHCM). Functions B and C evaluated mounted doses of EDG-7500 over 28 days in oHCM and nonobstructive HCM (nHCM), respectively; the outcomes is also stumbled on right here. Segment D is a 12-week compare in conjunction with participants with oHCM and nHCM designed to search out dose response and optimization, followed by an open-be conscious extension; the outcomes is also stumbled on right here. To be taught extra about CIRRUS-HCM, seek the advice of with clinicaltrials.gov, NCT06347159.
About Hypertrophic Cardiomyopathy
HCM is the most traditional invent of genetic coronary heart illness, affecting roughly one in 500 people, and is expounded to reduced quality of lifestyles and an elevated possibility of coronary heart failure, abnormal coronary heart rhythms, and unexpected cardiac death. Contributors with HCM can turn out to be extremely restricted in their purposeful skill and skill to fabricate the activities of day to day residing. Generally skilled symptoms encompass breathlessness, irregular heartbeat, chest wretchedness, tiredness, dizziness, or even fainting. These symptoms are triggered by low contraction and thickening (hypertrophy) of the left ventricular wall of the coronary heart. Over time, the thickened muscle becomes stiff, making it refined for the coronary heart to chill and have with blood (diastolic dysfunction). There are two predominant forms of HCM: obstructive and nonobstructive. Despite advancements in remedy strategies for some sufferers with HCM, there stays a predominant unmet want for additional therapeutic approaches for sufferers.
About Edgewise Therapeutics
Edgewise Therapeutics is a number one biopharmaceutical firm taking into consideration about growing innovative therapies for valuable cardiovascular and cardiometabolic illnesses. Leveraging its expertise in integrated muscle physiology and miniature molecule drug fashion, Edgewise is advancing a cardiovascular pipeline concentrated on valuable unmet needs, in conjunction with hypertrophic cardiomyopathy and coronary heart failure. To be taught extra, plug to edgewisetx.com or be conscious Edgewise on LinkedIn, X, Fb and Instagram.
This press liberate contains hyperlinks to recordsdata that is now not deemed to be integrated by reference into this press liberate.
Demand fashioned drawl to download multimedia: https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-upcoming-leisurely-breaking-science-presentation-at-the-european-society-of-cardiology-esc-congress-2026-302857842.html
SOURCE Edgewise Therapeutics
